Alpine Associates Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Alpine Associates Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-719,500	Closed	-$94.9M	–	68
2025 Q1	$94.9M	Buy	+719,500	New	+$89.7M	4.97%	6

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alpine Associates Management's ITCI Position: Q2 2025 in Review

Alpine Associates Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 719,500 shares — an estimated $94.9M sold.

Alpine Associates Management first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $94.9M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Alpine Associates Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Alpine Associates Management sold 719,500 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $94.9M.
Alpine Associates Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Alpine Associates Management's Intra-Cellular Therapies Inc. position peaked at $94.9M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Alpine Associates Management's 13F filing for Q2 2025, filed 5 Aug 2025.